VOTRIENT 400 mg, film-coated tablet 30 tablets
Active ingredients: Pazopanib, Pazopanib hydrochloride
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet30 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- VOTRIENT 400 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- flacon(s) polyéthylène haute densité (PEHD) de 30 comprimé(s)
- Marketing authorisation holder
- NOVARTIS EUROPHARM (IRLANDE)
- Reimbursement according to BDPM
- 100%
- Reimbursement conditions
- Ce médicament peut être pris en charge ou remboursé par l'Assurance Maladie dans les cas suivants :<br><br>- cancer du rein avancé, uniquement chez le patient non préalablement traités par des cytokines<br>- sarcome des tissus mous avancé ; JOURNAL OFFICIEL ; 22/11/13
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 15 Sept 2010
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
63803884CIP74913157CIP133400949131570Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| PAZOPANIBcomprimé | 400 mg · un comprimé | FT |
| PAZOPANIB (CHLORHYDRATE DE)comprimé | 433,4 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.